Rapid antimicrobial susceptibility testing (AST), when done right, has the potential to transform patient care—enabling timely, targeted therapy, reducing hospital stays, and supporting antimicrobial stewardship and quality initiatives. Yet with the recent withdrawal of first-generation rapid AST systems, many laboratories are reassessing their diagnostic approaches and exploring alternatives.

Join us on August 28, 2025 at 1pm EST for, "Rapid AST: the Next Generation is Here For You," to learn how LifeScale AST may offer a practical solution to this challenge.  LifeScale is a rapid AST FDA cleared for Gram-negative bacteremia, and improves on first-generation rapid ASTs in speed, accuracy, throughput, and convenience.  Its advanced population profiling technology generates reliable susceptibility results within 4 ½ hours, as proven in several field evaluations.  Dr. James Snyder, Director of Microbiology and Molecular Diagnostics at University of Louisville Health, will offer insights gained from his firsthand experience evaluating both the legacy Accelerate Pheno system and LifeScale.  And if you are considering rapid AST for the first time, this webinar will introduce rapid AST principles of operation and show how LifeScale can improve the care of your patients, enhance antimicrobial stewardship, and reduce the overall costs of care.

Explore the future of rapid AST—Register Now!